Finding a Path Through Alzheimer's Disease

Target Audience

The educational design of this activity addresses the needs of specialists (neurologists, geriatricians, radiologists) and primary care clinicians (physicians, nurse practitioners, and physician associates/assistants) who manage patients with mild cognitive impairment (MCI) or mild Alzheimer’s disease (AD).

Program Overview

This enduring Patient Journey™ activity follows a patient’s real-world experience from initial presentation through treatment with amyloid-targeted therapies (ATTs). This multimodal, interactive program employs a unique educational format that mirrors the clinical and emotional journey of a patient with MCI or mild AD across 5 “Mile Markers.” Dr. Marwan Sabbagh provides interpretive insights on practical strategies for detecting cognitive impairment, confirming an AD diagnosis, educating patients and caregivers, initiating ATT, managing amyloid-related imaging abnormalities (ARIA), and transitioning to maintenance dosing. Patient vignettes are woven throughout the activity to highlight shared decision making and the importance of a patient-centered care approach. 

Educational Objectives 

After completing this activity, the participant should be better able to:

• Incorporate a comprehensive assessment of cognition, daily function, and biomarkers to confirm an early AD diagnosis
• Educate patients and caregivers on AD progression and the risks and benefits of amyloid-targeted therapy (ATT)
• Create and continuously update a comprehensive, long-term management plan that includes ATTs, as appropriate
• Describe optimal strategies for detecting and managing amyloid-related imaging abnormalities (ARIA) in a patient receiving antiamyloid mAbs

Physician Accreditation Statement

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Integritas designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC’s Commission on Accreditation recognizes educational activities that are approved for AMA PRA Category 1 Credits™ by providers who are accredited by the ACCME to award credit to learners. This reciprocity agreement allows nurses and nurse practitioners to use AMA PRA Category 1 Credits™ as approved ANCC contact hours for license renewal.

Integritas Contact Information

For more information about the approval of this program, please contact Integritas at info@exchangecme.com. 

Instructions to Receive Credit

In order to receive credit for this activity, the participant must take the pretest, view the content, pass the posttest with a 70% or higher, and complete the evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas.  All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies:

Marwan Noel Sabbagh, MD, FAAN, FANA: Consulting Fees: Annovex Pharma, Inc., Cognito Therapeutics, Inc., Eisai Inc., Eli Lilly and Company, GlaxoSmithKline,  NeuroTherapia, Inc. Recall Therapeutics; Stock: Lighthouse Pharmaceuticals; Other: CervoMed Inc. 

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.